Abstract

Previously, there is no study looking at serum biomarkers for epilepsy. Epilepsy can trigger neuroinflammation events, and serum amyloid A (SAA) is one biomarker as acute-phase protein in multiple diseases. In present study, we detected serum SAA peak in epileptic patients with mass spectrometry and quantified with enzyme-linked immunosorbent assay measurement. The results suggested that in acute phase of epilepsy, the serum SAA increased, but after 3 months of treatment, the SAA peak was disappeared. In conclusion, the study provided values of proteomic diagnosis of epilepsy.